Search

Search Constraints

You searched for: Author/Creator Bhojwani, Deepa

Search Results

2. Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. Issue 9 (20th March 2022)

3. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Issue 4 (April 2015)

4. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Issue 4 (April 2015)

5. Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. Issue 5 (8th March 2022)

6. Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre‐transplant minimal residual disease reduction. Issue 1 (22nd September 2020)

7. HMGA1 overexpression correlates with relapse in childhood B-lineage acute lymphoblastic leukemia. Issue 11 (November 2013)

8. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome‐positive acute lymphoblastic leukemia. Issue 10 (5th February 2014)

9. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome‐positive acute lymphoblastic leukemia. Issue 10 (5th February 2014)

10. Investigating the biology of relapsed acute leukemia: Proceedings of the Therapeutic Advances for Childhood Leukemia & Lymphoma (TACL) Consortium Biology Working Group. (3rd October 2017)